Atenolol ………………….. 50 mg
Excipients q.s ……………………… 1 tablet
Film coated tablets.
Box of 3 blisters x 10 film coated tablets.
Teginol contains the main active ingredient - Atenolol which is an antihypertensive, anti-anginose agent used in the treatment of irregular polycardia.
The antihypertensive effect of atenolol is performed thanks to the following mechanisms:
Reduction in cardiac output and peripheral blocking.
Suppression of renin activity by the kidneys.
Reduction in central sympathetic tonicity due to antagonism with central beta-receptors.
The effect of cardiataxia treatment is shown according to the mechanism of prolongation of effective inert period of the atrioventricular node.
Angina pectoris occurs when the demand for oxygen by the heart exceeds the supply. By decreasing heart rate and myocardial contractility, atenolol generally reduces the oxygen requirements of the heart, making it useful for many patients with angina pectoris.
Atenolol is a selective inhibitor of beta1-receptors (on myocardium), seldom inhibits beta2-receptors; therefore, atenolol rarely causes the effects of peripheral, coronary, bronchial vasoconstriction. Atenolol is a water-soluble active ingredient, rarely infiltrates into central nervous system; so it does not induce headache like the oil-soluble beta-blockers.
Atenolol is not metabolized by the livers for the first time. The drug is eliminated by the kidneys. The half-life of Teginol is approximately 6 to 9 hours for individuals with normal renal function. The effects on pulse and blood pressure are longer and persist for at least 24 hours. When renal function is impaired, the half-life of Teginol is increased and is not influenced by liver disease.
It is advised to follow body reactions during administration of the drug because it can affect the ability to drive and operate machines in some cases.
As other beta-blockers, atenolol can cause bradycardia in foetus and newborn infants; the drug should be only used in the last trimester and nearly the period of birth if really necessary.
The drug should not be used in nursing mothers.
Concurrent administration of calcium channel blockers may induce severe hypotension, bradycardia, heart block. Concomitant use of drugs decreasing catecholamine and prasozine may occur postural acute hypotension. Concurrent use of quinidine and drugs of 1st-group anti-cardiataxia may cause the synergistic effect on myocardium.
Frequent: muscular impairment, lassitude, cold and chilly feeling on the head of legs. Diarrhea, nausea. Bradycardia with frequency < 50 times/ minute at rest.
Less frequent: dyssomnia, impaired sex.
Rare: dizziness, headache. Thrombocytopenia. Nightmare, hallucination, depression. Xerophthalmia, vision disorders. Serious heart failure, AV block, postural hypotension, dizziness. Lipsotrichia, skin rashes, psoriasis-like reactions and purpura.
Inform your physician about any adverse effects occur during the treatment.
Overdosage with Teginol has been reported with patients surviving acute doses as high as 5 g.
The predominant symptoms reported following Teginol overdose are lethargy, disorder of respiratory drive, wheezing, sinus pause and bradycardia, hypotension, bronchospasm …
Treatment of overdose should be directed to the removal of any unabsorbed drug by induced emesis, gastric lavage, or administration of activated charcoal. Other treatment modalities should be employed at the physician’s discretion and may include:
Bradycardia: Atropine intravenously. If there is no response to vagal blockage, give isoproterenol cautiously. In refractory cases, a transvenous cardiac pacemaker may be indicated.
Heart block (second or third degree): Isoproterenol or transvenous cardiac pacemaker.
Cardiac failure: Digitalize the patient and administer a diuretic. Glucagon has been reported to be useful.
Hypotension: Dopamine or adrenalin. Monitor blood pressure continuously.
Bronchospasm: Isoproterenol or terbulaline and/or aminophylline.
Hypoglycemia: Intravenous glucose.
Special caution should be exercised when administering Teginol to patients with bronchial asthma or other obstructed pneumopathy; concurrent use with anesthetics by the respiratory tract; co-administered with digitalis or drugs of 1st-group anti-cardiataxia because of causing severe bradycardia; patients with intermittent claudication and severe renal impairment.
For the treatment of hypertension, chronic stable angina pectoris, recent myocardial infarction (for the first 12 hours) and prophylaxis of post-myocardial infarction, and supraventricular tachycardia
Cardiac shock, overt cardiac failure, 2nd- and 3rd-degree AV block, bradycardia with clinical signs.
Avoid concurrent use with verapamil.
Hypertension: the initial dose is 25 to 50 mg once a day. If an optimal response is not achieved, the dosage should be increased to 100 mg a day or used in conjunction with diuretics or peripheral vasodilative drugs.
Angina pectoris: 50 - 100 mg/ day.
Supraventricular tachycardia: 50 - 100 mg/ day.
When renal function is impaired, the dosages should be reduced or prolonged their interval.
Or as directed by the physician.
Read the directions carefully before use.
Consult the physician for more information.
This drug is for prescriptions only.
Register an account - receive thousands of information
You will be one of the first to receive information, news, recruitment news... from Hau Giang Pharmaceutical as soon as possible. Register today to enjoy thousands of incentives from Hau Giang Pharmaceutical.
